Naxitamab: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 April 2025

  • curprev 18:0218:02, 27 April 2025 Alara E. Dagsali talk contribs 25,576 bytes +5 No edit summary
  • curprev 18:0118:01, 27 April 2025 Alara E. Dagsali talk contribs 25,571 bytes +25,571 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=naxitamab |aOrAn=a |drugClass=IgG1 monoclonal antibody directed against GD2 disialogangliosides |indicationType=treatment |indication=of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. |hasBlackBox..."
Retrieved from "https://www.wikidoc.org/index.php/Naxitamab"